Europe’s CHMP Recommends Approving AstraZeneca’s Asthma, Neuromuscular Disorder Treatments
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc’s (NASDAQ:AZN) Ultomiris (ravulizumab)…